



Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: FISHMAN=19B

In re Application of:	)	Conf. No.: 9164
	)	
Pnina FISHMAN et al.	)	Art Unit: Not Yet Known
	)	
U.S. Appln. No.: 10/565,238	)	Examiner: Not Yet Known
Filed: January 19, 2006	)	
	)	
I.A. No.: PCT/IL2005/001279	)	Washington D.C.
I.A. Filed: November 30, 2005	)	
	)	
For: A BIOLOGICAL MARKER FOR	)	September 13, 2006
INFLAMMATION	)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop Amendment  
401 Dulany Street  
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto.

Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. Other information being provided for the examiner's consideration follows:

PCT International Search Report dated March 17, 2006

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

*Jay M. Kornbau*  
By: *Reg #21,082, for*

Anne M. Kornbau  
Registration No. 25,884

AMK:ma  
624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528

G:\BN\C\cohn\Fishman19B\Pto\2006-09-12 IDS Form.doc



Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/565,238
Filing Date	January 19, 2006
First Named Inventor	Pnina FISHMAN
Confirmation No.	9164
Art Unit	Not Yet Known
Attorney Docket Number	FISHMAN=19B

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

**Complete if Known**

Application Number	10/565,238
Filing Date	January 19, 2006
First Named Inventor	Pnina FISHMAN
Group Art Unit	9164
Examiner Name	Not Yet Known
Attorney Docket Number	FISHMAN=19B

**NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AF	B. A. WALKER et al., "Adenosine A <sub>3</sub> receptor expression and function in eosinophils", <u>American Journal of Respiratory Cell and Molecular Biology</u> , Vol. 16, No. 5, pages 531-537, May 1997.	
	AG	P. G. BARALDI et al., "A <sub>3</sub> Adenosine Receptor Ligands: History and Perspectives", <u>Medicinal Research Reviews</u> , Vol. 20, No. 2, pages 103-128, March 2000.	
	AH	Y. KOHNO et al., "Activation of A <sub>3</sub> Adenosine Receptors on Human Eosinophils Elevates Intracellular Calcium", <u>Blood</u> , Vol. 88, No. 9, pages 3569-3574, November 1, 1996.	
	AI	P. FISHMAN et al., "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells", <u>Oncogene</u> , Vol. 21, pages 4060-4064, 2002.	
	AJ	P. FISHMAN et al., "Targeting the A <sub>3</sub> adenosine receptor for cancer therapy: inhibition of Prostate carcinoma cell growth by A <sub>3</sub> AR agonist", <u>Anticancer Res.</u> , Vol. 23, pages 2077-2083, 2003.	
	AK	L. MADI et al., "A <sub>3</sub> adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition", <u>J. Bio. Chem.</u> , Vol. 278, pages 42121-42130, 2003.	
	AL	G. OHANA et al., "Inhibition of primary colon carcinoma growth and liver metastasis by the A <sub>3</sub> adenosine receptor agonist IB-CF101", <u>British J. Cancer</u> , Vol. 89, pages 1552-1558, 2003.	
	AM	P. FISHMAN et al., "An agonist to the A <sub>3</sub> adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 $\beta$ and NF- $\kappa$ B", <u>Oncogene</u> , Vol. 23, pages 2465-2471, 2004.	
	AN	C. SZABO et al., "Suppression of macrophage inflammatory protein (MIP)-1 $\alpha$ production and collagen-induced arthritis by adenosine receptor agonists", <u>British J. Pharmacology</u> , Vol. 125, pages 379-387, 1998.	
	AO	J. MABLEY et al., "The adenosine A <sub>3</sub> receptor agonist, N <sup>6</sup> -(3-iodobenzyl)-adenosine -5'-N-methyluronamide, is protective in two murine models of colitis", <u>European J. Pharmacology</u> , Vol. 466, pages 323-329, 2003.	
	AP	E. BAHARAV et al., "The effect of adenosine and the A <sub>3</sub> adenosine receptor agonist IB-MECA on joint inflammation and autoimmune diseases models", <u>Inter. J. Mol. Med.</u> , Vol. 10 (supplement 1), page S104, abstract 499, 2002.	
	AQ	M. MONTESINOS et al., "Adenosine A <sub>2A</sub> or A <sub>3</sub> receptors are required for inhibition of inflammation by methotrexate and its analog MX-68", <u>Arthritis &amp; Rheumatism</u> , Vol. 48, pages 240-247, 2003.	
	AR	L. MADI et al., "The A <sub>3</sub> Adenosine Receptor is Highly Expressed in Tumor vs. Normal Cells: Potential Target for Tumor Growth Inhibition", <u>Clinical Cancer Research</u> , Vol. 10, pages 4472-4479, 2004.	
	AS	S. GESSI et al., "Elevated expression of A <sub>3</sub> adenosine receptors in human colorectal cancer is reflected in peripheral blood cells", <u>Clinical Cancer Research</u> , Vol. 10, pages 5895-5901, 2004.	
Examiner Signature			Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.